CN101342157A - Application of ocean bromine phenolic compound in preparing medicament for treating malignant tumor - Google Patents
Application of ocean bromine phenolic compound in preparing medicament for treating malignant tumor Download PDFInfo
- Publication number
- CN101342157A CN101342157A CNA2007100152998A CN200710015299A CN101342157A CN 101342157 A CN101342157 A CN 101342157A CN A2007100152998 A CNA2007100152998 A CN A2007100152998A CN 200710015299 A CN200710015299 A CN 200710015299A CN 101342157 A CN101342157 A CN 101342157A
- Authority
- CN
- China
- Prior art keywords
- bromo
- compound
- methyl
- malignant tumor
- ocean
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention relates to a medicine for treating malignant tumor, in particular to an application of seven oceanic bromophenol compounds to the preparation of the medicine for treating malignant tumor. The bromophenol compounds of the invention and the derivatives thereof such as salt, ester, aether, etc. have favorable inhibition effect on protein tyrosine kinase, and can be used for preventing and treating the malignant tumor of high expression C-kit receptor.
Description
Technical field
The present invention relates to treat the medicine of malignant tumor, specifically the preparation method of ocean bromine phenol compounds, pharmacologically active, purposes and pharmaceutically acceptable salt, ester, ether and other tangible chemical equivalence thing; (protein tyrosinekinase, PTK) inhibitor can be used for treating the malignant tumor of various high expressed C-kit receptors as protein tyrosine kinase for this chemical compound and derivant thereof.
Background technology
Along with the development that molecular weight tumor is learned, the research of antitumor drug also acts on the newtype drug of molecular target from traditional cell toxicity medicament trend.Protein tyrosine kinase (PTK) is one of target of treatment of cancer, proto-oncogene C-kit is the congener of HZ4 cat family sarcoma virus kit oncogene, be positioned at No. 4 chromosomes long-armed on, the coding 145-165kDa transmembrane receptor (CD117), have tyrosine kinase activity.Its product is an III type tyrosine protein kinase growth factor receptors, its similar is in M-CSF and platelet-derived thing growth factor receptors, belong to the immunoglobulin superfamily member, have outer 5 the immunoglobulin-like similar structures of born of the same parents ligand binding domain, stride membrane-proximal region and tyrosine protein kinase district in film district, the film.In normal structure, C-kit albumen is expressed at mastocyte, Interstitial cell, melanocyte and galactophore epithelial cell.The autocrine of C-kit signal path and paracrine stimulate the generation of participant's tumor, and play the effect of oncogene in kinds of tumors.C-kit albumen is somatomedin and stem cell factor (SCF) receptor, and the interaction between it and part stem cell factor can activate intrinsic tyrosine kinase, makes the intracellular protein phosphorylation thereupon, causes the activation of signal transduction path in the cell.Proto-oncogene C-kit sudden change can cause that the proteic extracellular fragment of C-kit or born of the same parents' inner segment change, cause C-kit protein receptor continuous openness, the continuous autophosphorylation of various substrate proteins, make the conducted signal cascade of characteristics such as regulating cell differentiation, propagation, apoptosis, chemotactic and adhesion discharge and expansion, promoted the cell growth by this approach, suppressed apoptosis, the normal biological characteristics of cell disappears and develops into tumor cell.The oncogenic potential of C-kit is confirmed in many experiments, discoveries such as Hines, transfection the MCF-7 breast cancer cell of the C-kit growth and the multiplication rate that tie up in the culture medium speed, and this propagation can be prevented by anti-C-kit antibody; Caruana etc. to transfection the reorganization NIH3T3 fibroblast of C-kit gene cultivate, find that the activation of C-kit can promote cell proliferation and produce the Phenotype of a variation that this has obtained confirmation in cell clone and nude mice tumor model.In recent years, more and more researchers research is sought the small molecular protein tyrosine kinase inhibitor, thereby is developed new type anticancer medicine efficiently about the tumor of C-kit receptor as molecule target treatment high expressed C-kit receptor.
From modern medicines research and development historical as seen, the Application and Development of each original new drug, at first from the discovery of certain class new type natural lead compound, the ocean is origin of life ground, in the unique ecological environment of ocean, Sargassum can produce some very distinctive active substances mostly.The inventor obtains the bromine phenolic compound of a novel structure from a kind of marine red alga, active testing shows that it has very strong inhibition activity to the PTK enzyme, can be used for the control of the malignant tumor of high expressed C-kit receptor, comprise gastrointestinal stromal tumor (GIST), Mastocytosis type leukemia, germ cell tumor, small cell lung cancer, acute leukemia, neuroblastoma, melanoma, ovarian cancer and breast carcinoma etc.
Summary of the invention
The object of the invention has provided the application of a class ocean bromine phenol class medicine in preparation treatment high expressed C-kit receptor malignant tumor medicine, derivants such as bromine phenolic compound and salt thereof, ester and ether have good inhibitory effect to protein tyrosine kinase, can be used for the control of the malignant tumor of high expressed C-kit receptor.
For achieving the above object, the technical solution used in the present invention is:
7 kinds have acceptable salt, ester, ether and other tangible chemical equivalence thing on protein tyrosine kinase (PTK) active ocean bromine phenol compounds of inhibition and the materia medica thereof, can be used for the control of the malignant tumor of high expressed C-kit receptor.
Bromine phenolic compound is respectively: Compound I 3,4-two bromo-5-(ethoxyl methyl)-1,2-biphenol (Chinese), 3,4-dibromo-5-(ethoxymethyl)-1,2-benzenediol (English), Compound I I 4,4 '-methylene-two (5,6-two bromo-1,2-two basic phenol) (Chinese), 4,4 '-methylenebis [5,6-dibromo-1,2-benzenediol] (English), compound III 3-bromo-4-[2,3-two bromo-4, the 5-dihydroxy phenyl]-methyl-5-(methoxy)-1,2-biphenol (Chinese), 3-bromo-4-[2,3-dibromo-4,5-dihydroxyphenyl] methyl-5-(methoxymethyl)-1,2-benzenediol (English), compound IV 3-bromo-4,5-dihydroxy-benzaldehyde (Chinese), 3-bromo-4,5-dihydroxy-benzaldehyde (English), chemical compound V 3-bromo-4-[2,3-two bromo-4, the 5-dihydroxy phenyl] methyl-5-(methylol)-1,2-biphenol (Chinese), 3-bromo-4-[2,3-dibromo-4,5-dihydroxyphenyl] methyl-5-(hydroxymethyl)-1,2-benzenediol (English), compound VI two (2,3-two bromo-4,5-dihydroxy benzenes methyl) ether (Chinese), and bis (2,3-dibromo-4,5-dihydroxybenzyl) ether (English), compound VI I 3-bromo-4-[2,3-two bromo-4, the 5-dihydroxy phenyl]-methyl-5-(ethyoxyl)-1,2-biphenol (Chinese), 3-bromo-4-[2,3-dibromo-4,5-dihydroxyphenyl] methyl-5-(ethoxymethyl)-1,2-benzenedio (English); Chemical constitution is as follows:
The extraction of bromine phenolic compound, separation and structure are identified:
Air-dry Rhodomela confervoides Rhodomela confervoides sample is pulverized back 95% ethanol extraction, extracting solution concentrating under reduced pressure; Concentrate is used ethyl acetate extraction, concentrating under reduced pressure after suspending with distilled water.Silica gel column chromatography is carried out at the ethyl acetate extraction position, with petroleum ether-acetone gradient elution, is 1: 1 until the two volume ratio, use the chloroform-methanol gradient elution instead, use 95% ethanol elution at last, the thin layer chromatography inspection, be merged into eluent like the phase-splitting, concentrating under reduced pressure gets 14 partial L
1～L
14
L
8Partly [petroleum ether: acetone=2: 1] eluting partly passes through aluminum oxide column chromatography, silica gel chromatography, recrystallization can get pure compound I, through Spectrum Analysis, this chemical compound is 3,4-two bromo-5-(ethoxyl methyl)-1,2-biphenol (Chinese), 3,4-dibromo-5-(ethoxymethyl)-1,2-benzenediol (English).
L
10Partly [chloroform: methanol=5: 1] eluting partly passes through silica gel chromatography, adopt chloroform-methanol to carry out gradient elution, can get pure compound II, through Spectrum Analysis, this chemical compound is 4,4 '-methylene-two (5,6-two bromo-1,2-two basic phenol) (Chinese), 4,4 '-methylenebis[5,6-dibromo-1,2-benzenediol] (English).
L
11Partly [chloroform: methanol=3: 1] eluting partly passes through silica gel chromatography, adopt chloroform-methanol to carry out gradient elution, recrystallization can get pure compound III, through Spectrum Analysis, this chemical compound is 3-bromo-4-[2,3-two bromo-4, the 5-dihydroxy phenyl]-methyl-5-(methoxy)-1,2-biphenol (Chinese), 3-bromo-4-[2,3-dibromo-4,5-dihydroxyphenyl] methyl-5-(methoxymethyl)-1,2-benzenediol (English).
L
9Partly [petroleum ether: acetone=1: 1] eluting partly passes through silica gel chromatography, Sephadex LH 20 gel chromatographies, the HPLC purification gets compound IV, through Spectrum Analysis, this chemical compound is a 3-bromo-4,5-dihydroxy-benzaldehyde (Chinese), 3-bromo-4,5-dihydroxy-benzaldehyde (English).
L
11Partly [chloroform: methanol=3: 1] eluting partly passes through silica gel chromatography, and chloroform-methanol is an eluant, crosses the Bio-beads post then respectively, the HPLC purification gets chemical compound V, through Spectrum Analysis, this chemical compound is 3-bromo-4-[2,3-two bromo-4, the 5-dihydroxy phenyl] methyl-5-(methylol)-1,2-biphenol (Chinese), 3-bromo-4-[2,3-dibromo-4,5-dihydroxyphenyl] methyl-5-(hydroxymethyl)-1,2-benzenediol (English).
L
10Partly [chloroform: methanol=5: 1] eluting partly passes through silica gel chromatography, Sephadex LH 20 gel chromatographies, the HPLC purification gets compound VI, through Spectrum Analysis, this chemical compound be two (2,3-two bromo-4,5-dihydroxy benzenes methyl) ether (Chinese), bis (2,3-dibromo-4,5-dihydroxybenzyl) ether (English).
L
11Partly [chloroform: methanol=3: 1] eluting partly passes through silica gel chromatography, chloroform-methanol is an eluant, gets compound VI I through the HPLC purification then, through Spectrum Analysis, this chemical compound is 3-bromo-4-[2,3-two bromo-4, the 5-dihydroxy phenyl]-methyl-5-(ethyoxyl)-1,2-biphenol (Chinese), 3-bromo-4-[2,3-dibromo-4,5-dihydroxyphenyl] methyl-5-(ethoxymethyl)-1,2-benzenedio (English).
Tyrosine kinase activity suppresses active testing:
Adopt enzyme-linked immunosorbent assay (ELISA), receptor kinase is C-kit, positive control medicine Glivic (imatinib mesylate).
The vicious transformation of cell and growth are relevant with tyrosine kinase expression in the cell, and tyrosine kinase inhibitor can be blocked those growths that has tyrosine kinase overexpression and the active tumor cell that increases, and suppress the propagation of tumor cell.The most cells growth factor receptors contains the peptide chain-ordering of tyrosine kinase, so this receptoroid is commonly referred to as tyrosine kinase receptor.According to the similarity and the construction features of peptide chain-ordering, these receptors are divided into some families: the 1st class is representative with epithelial growth factor receptor (EGFR), and the high expressed of this receptoroid is common in the epithelial cell tumor; The 2nd class is an Insulin Receptor Family, comprises Insulin receptor INSR, IGF-1 (IGF-R) and insulin associated receptor (IRR) etc., the high expressed of common this receptoroid in the blood cell tumor; The 3rd class is platelet-derived growth factor receptors (PDGFR) family, comprises PDGFR α, PDGF β, and clone's stimulating factor (CSF-1a), C-kit etc., this receptoroid is common high expressed in the cerebral tumor and blood cell tumor etc.; The 4th class is bfgf receptor (FGFR) family, includes FGFR1, FGFR2, and FGFR3, FGFR4 and keratinocyte growth factor receptor etc., this receptoroid plays an important role aspect angiogenesis; The 5th class is vascular endothelial growth factor receptor (VEGFR), is the important positivity regulatory factor of angiogenesis; In addition, also have C-MET HGFr (HGFR) class, Fibroneetin III receptor class and nerve growth factor acceptor (NGFR) family etc.
The C-kit receptor is as type iii protein tyrosine kinase receptor superfamily member, utilize protein tyrosine kinase inhibitor can suppress the kinds of tumors that its kinase activity is treated high expressed C-kit receptor, by effect C-kit receptor, suppress the tyrosine receptor phosphorylation, suppress the tyrosine kinase abnormal activation, thereby suppress the kinds of tumors of high expressed C-kit receptor effectively.
The present invention has following advantage: (1), source are abundant: China is ocean big country, has abundant living marine resources, and marine algae resource distributes especially extensive.(2), evident in efficacy: as the multi-halogenated compounds that has the ocean characteristic, bromine phenols medicine is a kind of novel, tyrosine kinase inhibitor efficiently, shows significant antitumor curative effect in melanin mice with tumor body.(3), side effect is little: bromine phenols medicament sources Yu Haiyang red algae, the genus pure natural biological product is compared chemosynthesis class medicine and is had the advantage of high-efficiency low-toxicity.
The specific embodiment
The extraction of embodiment 1 bromine phenolic compound, separation and structure are identified
Air-dry Rhodomela confervoides Rhodomela confervoides sample 14.4kg (dry weight) pulverizes back 10L95% ethanol extraction three times, each 72 hours; Merge lixiviating solution, 40 ℃ of following concentrating under reduced pressure of extracting solution get ethanol extraction 723g, after concentrate suspends with 10 times of weight distilled water, use the equal-volume ethyl acetate extraction, concentrating under reduced pressure, get ethyl acetate phase extractum 594.6g, silica gel column chromatography is carried out at the ethyl acetate extraction position, with petroleum ether-acetone gradient elution (volume ratio 500: 1～1: 1), be 1: 1 until the two volume ratio, use chloroform-methanol gradient elution (volume ratio 20: 1～1: 1) instead, use 95% ethanol elution at last, thin layer chromatography checks, is merged into eluent like the phase-splitting, and concentrating under reduced pressure gets 14 partial L
1～L
14
L
8Partly [petroleum ether: acetone volume ratio=2: 1] eluting partly passes through aluminum oxide column chromatography, silica gel chromatography [petroleum ether: ethyl acetate volume ratio=7: 1], recrystallization [petroleum ether: ethyl acetate=5: 1] can get pure compound I, through Spectrum Analysis, this chemical compound is 3,4-two bromo-5-(ethoxyl methyl)-1,2-biphenol (Chinese), 3,4-dibromo-5-(ethoxymethyl)-1,2-benzenediol (English).
L
10Partly [chloroform: methanol volume ratio=5: 1] eluting partly passes through silica gel chromatography, adopt chloroform-methanol to carry out gradient elution, can get pure compound II, through Spectrum Analysis, this chemical compound is 4,4 '-methylene-two (5,6-two bromo-1,2-two basic phenol) (Chinese), 4,4 '-methylenebis[5,6-dibromo-1,2-benzenediol] (English).
L
11Partly [chloroform: methanol volume ratio=3: 1] eluting partly passes through silica gel chromatography, adopt chloroform-methanol (50: 1-20: 1-10: 1-5: 1) carry out gradient elution, recrystallization can get pure compound III, through Spectrum Analysis, this chemical compound is 3-bromo-4-[2,3-two bromo-4, the 5-dihydroxy phenyl]-methyl-5-(methoxy)-1,2-biphenol (Chinese), 3-bromo-4-[2,3-dibromo-4,5-dihydroxyphenyl] methyl-5-(methoxymethyl)-1,2-benzenediol (English).
L
9Partly [petroleum ether: acetone volume ratio=1: 1] eluting partly passes through silica gel chromatography, Sephadex LH20 gel chromatography [petroleum ether: chloroform: methanol=5: 5: 1], HPLC[methanol: water: acetic acid=80%: 20%: 0.1%] purification gets compound IV, through Spectrum Analysis, this chemical compound is a 3-bromo-4,5-dihydroxy-benzaldehyde (Chinese), 3-bromo-4,5-dihydroxy-benzaldehyde (English).
L
11Partly [chloroform: methanol volume ratio=3: 1] eluting partly passes through silica gel chromatography, chloroform-methanol is an eluant, cross Bio-beads (chloroform: ethyl acetate 1: 1) then respectively, the HPLC purification gets chemical compound V, through Spectrum Analysis, this chemical compound is 3-bromo-4-[2,3-two bromo-4, the 5-dihydroxy phenyl] methyl-5-(methylol)-1,2-biphenol (Chinese), 3-bromo-4-[2,3-dibromo-4,5-dihydroxyphenyl] methyl-5-(hydroxymethyl)-1,2-benzenediol (English).
L
10Partly [chloroform: methanol volume ratio=5: 1] eluting partly passes through silica gel chromatography, Sephadex LH20 gel chromatography [petroleum ether: chloroform: methanol=5: 5: 1], the HPLC purification gets compound VI, through Spectrum Analysis, this chemical compound be two (2,3-two bromo-4,5-dihydroxy benzenes methyl) ether (Chinese), bis (2,3-dibromo-4,5-dihydroxybenzyl) ether (English).
L
11Partly [chloroform: methanol volume ratio=3: 1] eluting partly passes through silica gel chromatography, chloroform-methanol is an eluant, gets compound VI I through the HPLC purification then, through Spectrum Analysis, this chemical compound is 3-bromo-4-[2,3-two bromo-4, the 5-dihydroxy phenyl]-methyl-5-(ethyoxyl)-1,2-biphenol (Chinese), 3-bromo-4-[2,3-dibromo-4,5-dihydroxyphenyl] methyl-5-(ethoxymethyl)-1,2-benzenedio (English).
Embodiment 2 tyrosine kinase activities suppress the active property surveyed
Adopt the double-antibody sandwich elisa method.Press the explanation of C-kit test kit, compound sample is diluted to finite concentration (1 μ g/mL) to join in 96 orifice plates, except that blank well, add 100 μ L serum specimens respectively, add biotinylated antibody working solution 50 μ L again, hatch 60min in 25 ℃ behind the mixing, wash plate 4 times, respectively at the Avidin 100 μ L of each hole (comprising blank well) adding horseradish peroxidase labelling, hatch 30min in 25 ℃.Add substrate colour developing liquid (OPD) 100 μ L behind each hole lucifuge incubated at room 15min, the absorbance value that every hole adds stop buffer (1.8N sulphuric acid) 100 μ L and places detector to measure 490nm immediately detects substrate phosphorylation.Positive control: Glivic (imatinib mesylate), can be competitively in conjunction with C-kit SRCA TP in conjunction with the territory, suppress the tyrosine receptor phosphorylation.
The suppression ratio (%) of table 1 pair protein hydroxyphenylaminopropionic acid kinase activity
Figure?1?Inhibition?of?protein?tyrosine?kinase
[experiment conclusion]: bromine phenolic compound has good inhibitory effect to protein tyrosine kinase, can be used for the control of the malignant tumor of high expressed C-kit receptor.
Animal experiment in embodiment 3 bodies
1, experiment material
(1) tumor strain
B
16Melanoma cell, institute of materia medica, the Academy of Medical Sciences, Shandong pharmacological room provides.
(2) laboratory animal
Qingdao City's Experimental Animal Center provides C57BL/6 mice, male and female half and half, body weight 20 ± 2g, 6～8 ages in week.
2, test method
(1) mice B
16The modeling of melanoma mice with tumor
The B16 melanoma cell suspension concentration that incubation growth is vigorous is adjusted to 1 * 10
6/ mL in mice left side back subcutaneous injection B16 melanoma cell suspension 0.2mL/ only, finishes in the whole operation process 30min under the aseptic condition; Be divided into 4 groups behind the 24h at random, 10/group, male and female half and half divide cage to feed.
(2) grouping and administration
Organized by examination: to use the dimethyl sulfoxide (DMSO) of weight concentration 30% to dissolve respectively bromine phenolic compound, become corresponding administration concentration (being respectively 7 groups of 1 group-medicines of medicine) according to the 150mg/Kg dose dilution; Blank group (30% dimethyl sulfoxide); Positive controls (dacarbazine of 60mg/Kg).
From inoculating the 5th day, once a day, lumbar injection (i.p) administration is 14 days continuously, observes the mice growing state.Behind the last administration 24h, mice is put to death in the cervical vertebra dislocation, gets the tumor piece and weighs, and calculates the suppression ratio (tumour inhibiting rate) of tumor growth.
(3) index detects
Tumour inhibiting rate (%)=(the average tumor of the average tumor weight-experimental group of blank group is heavy)/average tumor of blank group heavy * 100%
See Table 2.The result shows that the average tumor weight average of medicine group and positive controls is lower than the blank group, and the tumor that its Chinese medicine is 3 groups tumor heavy and positive controls is heavy all to have significance with blank group comparing difference.* represents with the blank group significant difference (P＜0.05) is arranged relatively in the table.
Table 2 mouse tumor heavily reach tumour inhibiting rate (± s, n=10)
Table?2?Weight?of?Tumor?and?Inhibition?Ratios(±s，n＝10)
Claims (2)
1. the application of ocean bromine phenolic compound in preparation treatment malignant tumor medicine, it is characterized in that: described ocean bromine phenol compounds is respectively: 3,4-two bromo-5-(ethoxyl methyl)-1,2-biphenol Compound I, 4,4 '-methylene-two (5,6-two bromo-1,2-two basic phenol) Compound I I, 3-bromo-4-[2,3-two bromo-4, the 5-dihydroxy phenyl]-methyl-5-(methoxy)-1,2-biphenol compound III, 3-bromo-4,5-dihydroxy-benzaldehyde compound IV, 3-bromo-4-[2,3-two bromo-4,5-dihydroxy phenyl] methyl-5-(methylol)-1,2-biphenol chemical compound V, two (2,3-two bromo-4,5-dihydroxy benzenes methyl) ether compound VI, 3-bromo-4-[2,3-two bromo-4, the 5-dihydroxy phenyl]-methyl-5-(ethyoxyl)-1, acceptable salt on 2-biphenol compound VI I and the materia medica thereof, ester or ether.
2. according to the application of the described ocean bromine phenolic compound of claim 1 in preparation treatment malignant tumor medicine, it is characterized in that: described preparation treatment malignant tumor medicine is meant the malignant tumor medicine of the various high expressed C-kit receptors of preparation treatment.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2007100152998A CN101342157A (en) | 2007-07-13 | 2007-07-13 | Application of ocean bromine phenolic compound in preparing medicament for treating malignant tumor |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2007100152998A CN101342157A (en) | 2007-07-13 | 2007-07-13 | Application of ocean bromine phenolic compound in preparing medicament for treating malignant tumor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101342157A true CN101342157A (en) | 2009-01-14 |
Family
ID=40244351
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2007100152998A Pending CN101342157A (en) | 2007-07-13 | 2007-07-13 | Application of ocean bromine phenolic compound in preparing medicament for treating malignant tumor |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101342157A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102018691A (en) * | 2010-04-13 | 2011-04-20 | 中国科学院海洋研究所 | Medicament for treating thrombotic cardiovascular and cerebrovascular diseases and application thereof |
| CN102911182A (en) * | 2012-10-12 | 2013-02-06 | 鲁东大学 | Bromophenol compound and application thereof |
| CN103961340A (en) * | 2014-04-30 | 2014-08-06 | 中国科学院海洋研究所 | LSD1 inhibitors and application thereof |
| CN115025074A (en) * | 2021-03-05 | 2022-09-09 | 中国海洋大学 | Novel bromophenol compound DBBD (DBBD) with anti-tumor effect |
| CN115770235A (en) * | 2021-09-06 | 2023-03-10 | 中国海洋大学 | Application of bromophenol compound in resisting generation of tumor neovascularization |
-
2007
- 2007-07-13 CN CNA2007100152998A patent/CN101342157A/en active Pending
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102018691A (en) * | 2010-04-13 | 2011-04-20 | 中国科学院海洋研究所 | Medicament for treating thrombotic cardiovascular and cerebrovascular diseases and application thereof |
| CN102018691B (en) * | 2010-04-13 | 2013-03-27 | 中国科学院海洋研究所 | Medicament for treating thrombotic cardiovascular and cerebrovascular diseases and application thereof |
| CN102911182A (en) * | 2012-10-12 | 2013-02-06 | 鲁东大学 | Bromophenol compound and application thereof |
| CN102911182B (en) * | 2012-10-12 | 2014-12-10 | 鲁东大学 | Bromophenol compound and application thereof |
| CN103961340A (en) * | 2014-04-30 | 2014-08-06 | 中国科学院海洋研究所 | LSD1 inhibitors and application thereof |
| CN103961340B (en) * | 2014-04-30 | 2019-06-25 | 南通中国科学院海洋研究所海洋科学与技术研究发展中心 | A kind of LSD1 inhibitor and its application |
| CN115025074A (en) * | 2021-03-05 | 2022-09-09 | 中国海洋大学 | Novel bromophenol compound DBBD (DBBD) with anti-tumor effect |
| CN115770235A (en) * | 2021-09-06 | 2023-03-10 | 中国海洋大学 | Application of bromophenol compound in resisting generation of tumor neovascularization |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI732754B (en) | An extract from indigo naturalis and a process for preparing the same | |
| Ilinskaya et al. | Binase induces apoptosis of transformed myeloid cells and does not induce T-cell immune response | |
| Xie et al. | Ganoderma lucidum inhibits tumour cell proliferation and induces tumour cell death | |
| CN101342157A (en) | Application of ocean bromine phenolic compound in preparing medicament for treating malignant tumor | |
| CN101342158B (en) | Application of two bromine phenolic compounds in preparing medicament for treating malignant tumor | |
| Li et al. | Silibinin promotes the apoptosis of gastric cancer BGC823 cells through caspase pathway | |
| Ma et al. | Asiaticoside antagonizes proliferation and chemotherapeutic drug resistance in hepatocellular carcinoma (HCC) cells | |
| Xu et al. | Targeting tumor microenvironment: Effects of chinese herbal formulae on macrophage‐mediated lung cancer in mice | |
| Xiao-Pei et al. | Systematic identification of Celastrol-binding proteins reveals that Shoc2 is inhibited by Celastrol | |
| Wang et al. | Active fractions of golden-flowered tea (Camellia nitidissima Chi) inhibit epidermal growth factor receptor mutated non-small cell lung cancer via multiple pathways and targets in vitro and in vivo | |
| CN107536833B (en) | Application of 4-hydroxy-2-pyridone alkaloid in preparation of anti-tumor product | |
| Wang et al. | Therapeutic mechanism and effect of camptothecin on dextran sodium sulfate‐induced ulcerative colitis in mice | |
| CN107021942B (en) | Bark extract of Pinus Dabiennis, its preparation method and its application in pharmacy | |
| CN100998805A (en) | Biporia strengthening the body resistance anticancer preparation and its preparation method | |
| CN101283998B (en) | Application of bromine phenolic compound in preparing the medicine for curing the malignancy | |
| CN105213366B (en) | The medical usage and its pharmaceutical composition of gamboge ketone compound | |
| CN101456854A (en) | Medicine novel use of procyanidine oligomer and multimer | |
| CN109908188A (en) | A kind of Phellinus anti-cancer effective component extract and its preparation method and purposes | |
| Jiang et al. | Antineoplastic effects and mechanisms of a new RGD chimeric peptide from bullfrog skin on the proliferation and apoptosis of B16F10 cells | |
| Cao et al. | Total saponins from Rubus parvifolius L. inhibits cell proliferation, migration and invasion of malignant melanoma in vitro and in vivo | |
| Chen et al. | Oridonin inhibits the occurrence and development of colorectal cancer by reversing the Warburg effect via reducing PKM2 dimer formation and preventing its entry into the nucleus | |
| Fukagawa et al. | Antitumour effects of intravenous administration of BK-UM, a novel inhibitor of HB-EGF, in ovarian cancer therapy | |
| CN110776409B (en) | Method for extracting pterocarpus indicus and application of extract in antitumor drugs | |
| CN110437149B (en) | Natural naphthyl isoquinoline compound with antitumor activity, and composition and application thereof | |
| CN105524135B (en) | The preparation method and its application in preparation of anti-tumor drugs of straw berry tomato lactone |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20090114 |